• Home
  • Press Releases
  • Newsletters
  • About Us
  • Services
  • Contact
  •  
  •  
  • Support
  • Home
  • Press Releases
  • Newsletters
  • About Us
  • Services
  • Contact
  •  
  •  
  • Support

The Quinism Foundation Reemphasizes the Need for Caution in the Investigational and Off-Label Use of Tafenoquine Against COVID-19

November 22, 2021

The Neurotoxic Army-Developed Antimalarial Drug is Structurally Related to Hydroxychloroquine and Chloroquine and Carries a Risk of Potentially Severe Neuropsychiatric Adverse Effects

Read More 

The Quinism Foundation Encourages Those Injured by Hydroxychloroquine and Related Quinoline Antimalarial Drugs to File Timely Claims for Government Compensation

March 19, 2021

The Foundation has Written to Newly Confirmed Secretary of Health and Human Services, Xavier Becerra, Encouraging Liberal Consideration of Claims under the Countermeasures Injury Compensation Program

Read More 

The Quinism Foundation Renews Its Call for Congress to Fund Veteran-Focused Research into Mefloquine Neurotoxicity and Chronic Quinoline Encephalopathy

February 10, 2021

The National Academies of Sciences, Engineering and Medicine Finds Research is Needed into the Chronic Adverse Effects of Mefloquine and Related Quinoline Antimalarial Drugs

Read More 

The Quinism Foundation Now Offers Disability Evaluation Services to U.S. Veterans

February 8, 2021

Services Will Aid U.S. Veterans Seeking VA Disability Benefits From the Neurotoxic Effects of Mefloquine and Related Quinoline Drugs

Read More 

The Quinism Foundation Urges Caution in the Investigational and Off-Label Use of Tafenoquine Against COVID‑19

July 22, 2020

The Neurotoxic Army-Developed Antimalarial Drug is Structurally Related to Hydroxychloroquine and Chloroquine and Carries a Risk of Potentially Severe Neuropsychiatric Adverse Effects

Read More 

The Quinism Foundation Calls on State Boards of Pharmacy to Enact Uniform Restrictions to Limit Hoarding of Quinoline Antimalarial Drugs Against COVID-19

March 23, 2020

Limiting Restrictions to Hydroxychloroquine Only Risks Substitution of More Dangerous Quinolines for Off-Label Self-Treatment and Prophylaxis of Disease

Read More 

The Quinism Foundation Warns of Dangers from Use of Antimalarial Quinolines Against COVID-19

March 19, 2020

Use of Chloroquine, Hydroxychloroquine, Mefloquine, Quinine, and Related Quinoline Drugs Risks Sudden and Lasting Neuropsychiatric Effects from Idiosyncratic Neurotoxicity

Read More 

The Quinism Foundation and Veterans for Common Sense Call on Congress to Fund Research into Chronic Quinoline Encephalopathy

March 9, 2020

The National Academies of Sciences, Engineering, and Medicine Finds Research is Needed into the Chronic Adverse Effects of Mefloquine and Related Quinoline Antimalarial Drugs

Read More 

The Quinism Foundation Calls on GSK to Take Action to Better Emphasize Limitations of Use for Krintafel® (Tafenoquine)

February 28, 2020

Despite Published CDC Recommendations, Krintafel® is Not Indicated by the FDA for Use in Presumptive Anti-Relapse Therapy

Read More 

The Quinism Foundation Calls on the U.K. Science Media Centre to Issue an Immediate Correction to a Potentially Endangering Release on the Risk Profile of Mefloquine

August 8, 2019

The Release Contains Statements Which Potentially Pose a Direct Threat to the Traveling Public’s Health by Undermining Important Warnings Recently Mandated by Drug Regulators to Reduce the Risk of Serious Disabling and Potentially Life-Threatening Adverse Effects From the Drug

Read More 

The Quinism Foundation Holds Its Second Annual Meeting in White River Junction, Vermont

April 23, 2019

The Foundation Supports Education and Research on Chronic Quinoline Encephalopathy, a Medical Condition That Can Mimic PTSD

Read More 

The Quinism Foundation Calls on The National Academies Committee Investigating the Long-Term Effects of Mefloquine to Conduct Its Own Review of Veterans’ Medical Records

March 27, 2019

Several Veterans Will Travel to Washington, DC to Attend the Second Meeting of the Committee to Tell Committee Members Their Case Reports of Long-Term Effects Went Unpublished by the U.S. Military and the Centers for Disease Control and Prevention

Read More 

The Quinism Foundation Will Address a Committee of the National Academies Investigating the Long-Term Adverse Health Effects of Mefloquine Among Veterans

January 28, 2019

The Foundation Cautions the Department of Veterans Affairs (VA) Against Delaying Long-Overdue Action to Screen Veterans for Mefloquine Exposure Pending the Completion of the 18-Month Study

Read More 

The Quinism Foundation Calls on the Peace Corps to Deprioritize Use of Mefloquine and Investigate Claims of Misuse

December 12, 2018

Recent Media Reports Have Highlighted the Plight of Peace Corps Volunteers Left Permanently Disabled from the Antimalarial Drug

Read More 

The Quinism Foundation Expresses Concern That Department of Veterans Affairs (VA) Disability Examiners Are Misattributing Chronic Adverse Effects of Mefloquine to PTSD

November 29, 2018

Although DSM-5 Diagnostic Criteria Exclude the Diagnosis of PTSD if Symptoms Such as Insomnia and Nightmares Are Attributable to Medication Effects, VA Disability Examiners Do Not Routinely Screen Veterans for a History of Symptomatic Mefloquine Exposure

Read More 

The Quinism Foundation Shares its Concerns with Theranexus Regarding its Drug Candidate THN201

October 8, 2018

Mefloquine, a Component of TNH201, May Cause Neuropsychiatric Adverse Effects Including Cognitive Dysfunction and Nightmares That May Last Years After Use

Read More 

The Quinism Foundation Calls on Veterans Affairs Canada to Screen Recent Canadian Veterans for Symptomatic Mefloquine Exposure

September 19, 2018

Health Canada Warns that the Antimalarial Drug, Widely Prescribed to Members of the Canadian Armed Forces Since the Early 1990s, Can Cause Several Potentially Permanent and Disabling Conditions

Read More 

The Quinism Foundation Partners with Lifemark Health Group to Identify Canadian Veterans at Risk from Exposure to the Antimalarial Drug Mefloquine

September 17, 2018

The Foundation Announces a Pilot Program to License the Two-Question White River Mefloquine Instrument (WRMI-2) to Assist in Identifying Canadian Veterans with Disability from Dizziness, Balance Issues, and Other Conditions Potentially Caused by Mefloquine Exposure

Read More 

The Quinism Foundation Calls on the Department of Defense to Use Tafenoquine Only as a Drug of Last Resort for the Prevention of Malaria

September 5, 2018

Use of Tafenoquine During Military Deployments Could Lead to Adverse Effects Including Insomnia, Nightmares, and Anxiety Being Misattributed to the Sleep-Disrupting Effects of Travel or to the Effects of Trauma and Other Stressors.

Read More 

The Quinism Foundation Calls on the CDC to Update its Malaria Prevention Recommendations to Reflect Important FDA Safety Warnings for Tafenoquine and Mefloquine

August 14, 2018

The Foundation Warns that Psychiatric Symptoms Including Insomnia, Abnormal Dreams, and Nightmares Should be Considered Prodromal to More Serious Adverse Effects.

Read More 

The Quinism Foundation Partners with the National Centre for Trauma to Screen U.K. Veterans for Symptomatic Mefloquine Exposure

July 30, 2018

Use of the Two-Question White River Mefloquine Instrument (WRMI-2) Will Permit the National Centre for Trauma to Identify Veterans at Risk of Mefloquine Poisoning.

Read More 

The Quinism Foundation Urges Caution in the Use of Tafenoquine (Krintafel®) for the Prevention of Relapse of P. vivax Malaria

July 24, 2018

The Foundation has Shared Its Concerns for the Safety of the Newly-Approved Drug with the Bill & Melinda Gates Foundation and Medicines for Malaria Venture

Read More 

The Quinism Foundation Shares Its Concerns that the GlaxoSmithKline (GSK) Antimalarial Drug Tafenoquine is Neurotoxic

July 10, 2018

The Foundation has Shared with GSK its Report Submitted to FDA in Advance of the July 12, 2018 Meeting of the Antimicrobial Drugs Advisory Committee at Which New Drug Application (NDA) 210795 Will be Considered

Read More 

The Quinism Foundation Calls on the Department of Veterans Affairs to Update its Mefloquine Website

June 26, 2018

Veterans and VA Health Care Providers Must Be Provided With Up-To-Date Information That Accurately Reflects the Health Risks Posed by the Neurotoxic Drug

Read More 

The Quinism Foundation Calls on the Department of Veterans Affairs to Screen Recent Veterans for Symptomatic Mefloquine Exposure

May 29, 2018

The Antimalarial Drug Can Cause Chronic Neurologic and Psychiatric Effects Among Some Veterans, but the Government Does Not Know How Many Veterans Were Exposed, and Which Veterans Are Suffering Symptoms of Poisoning from their Exposure

Read More 

The Quinism Foundation Will Hold Its First Annual Meeting in White River Junction, Vermont

April 23, 2018

The Foundation Supports Education and Research on Chronic Quinoline Encephalopathy, a Medical Condition That Can Mimic PTSD

Read More 

The Quinism Foundation Joins Peace Corps Alumni Groups in Calling on NPR to Air Its Cancelled Report on Mefloquine

March 15, 2018

The Investigative Report on Mefloquine Use in the Peace Corps Was Cancelled Only Days Before Its Scheduled Airing in November 2017

Read More 

The Quinism Foundation Calls for a Reopening of the Somalia Commission of Inquiry

March 12, 2018

On the Quarter Century Anniversary of the Death of Shidane Arone, Mounting Evidence Exposes the Need to Investigate the Role of Mefloquine Poisoning in the Incident

Read More 

The Quinism Foundation Supports Australian Veterans’ Calls for Chronic Quinoline Encephalopathy to be Recognized as a Compensable Disorder

February 12, 2018

The Foundation Supports the Quinoline Veterans and Families Association in its Submission Related to Poisoning by Mefloquine, Tafenoquine, and Primaquine

Read More 

The Quinism Foundation Calls on Public Health England to Update its Malaria Chemoprophylaxis Recommendations

February 1, 2018

UK Drug Regulators Now Warn that Symptoms of Sleep Disturbance During Use of Mefloquine Require the Drug's Immediate Discontinuation

Read More 

The Quinism Foundation Incorporates As a Non-profit Corporation

January 24, 2018

The Foundation Supports Education and Research on Chronic Quinoline Encephalopathy, a Medical Condition That Can Mimic PTSD

Read More 
Join Our Email List

Recent Press Releases
  • The Quinism Foundation Reemphasizes the Need for Caution in the Investigational and Off-Label Use of Tafenoquine Against COVID-19
  • The Quinism Foundation Encourages Those Injured by Hydroxychloroquine and Related Quinoline Antimalarial Drugs to File Timely Claims for Government Compensation
  • The Quinism Foundation Renews Its Call for Congress to Fund Veteran-Focused Research into Mefloquine Neurotoxicity and Chronic Quinoline Encephalopathy
  • The Quinism Foundation Now Offers Disability Evaluation Services to U.S. Veterans
  • The Quinism Foundation Urges Caution in the Investigational and Off-Label Use of Tafenoquine Against COVID‑19
QF logo
Site Map

Home
Press Releases
Newsletters
About Us
Contact

Social

Facebook
Twitter
Support

Contact Us
  • The Quinism Foundation
    P.O. Box 145
    White River Junction, Vermont 05001 USA
  • quinism@quinism.org